RETRACTED ARTICLE: Effect of hCMSCs and liraglutide combination in ALI through cAMP/PKAc/β-catenin signaling pathway

Feng, Yun; Wang, Linlin; Ma, Xiaoying; Yang, Xiudong; Don, Ocholi; Chen, Xiaoyan; Jian, Qu; Song, Yuanlin

doi:10.1186/s13287-019-1492-6

Cited by 27 publications

(19 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, DPP4 inhibitors could be continued, at least in mild cases of COVID-19, while potential benefit in treating CoV infection remains to be studied further [78]. Similarly, GLP-1RAs are known to have anti-inflammatory effects and have shown potential for therapeutic benefit in acute lung injury [79]. However data are limited to experimental models and their benefit, at best, remains speculative.…”

Section: Specific Therapies For Covid-19 In People With Diabetesmentioning

confidence: 99%

Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature

et al. 2020

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic has emerged as one of the greatest challenges faced by humankind in the recent past. People with diabetes and related comorbidities are at increased risk of its complications and of COVID-19-related death. Older age, multi-morbidity, hyperglycaemia, cardiac injury and severe inflammatory response are predictors of poor outcome. The complex interplay between COVID-19, diabetes and the effects of related therapies is being explored. Most patients experience a mild illness with COVID-19, while people with diabetes are at increased risk of severe disease. Optimising glycaemic control and adopting measures to prevent disease spread are critical aspects. The management of mild disease is supportive, while very many immunomodulatory and antiviral therapies are being investigated for the treatment of severe disease. Several of these agents have specific considerations for use in people with diabetes. Since mass population lockdowns are considered a key step in controlling disease spread, it follows that, in addition to the direct vulnerability to severe COVID-19, people with diabetes can be affected by limited access to healthcare, insulin, other medications and blood glucose monitoring equipment. Measures to prevent disease spread at the individual and community level are the key to mitigating the rapidly escalating pandemic, while agents for chemoprophylaxis and vaccines are being explored. People with diabetes should be recognised as a vulnerable group for complicated disease and are at risk during times of disturbed social systems. Strategies are needed to safeguard the health of patients with diabetes during the pandemic. This review summarises the current knowledge and perceived challenges for prevention and management of COVID-19 in people with diabetes.

show abstract

Section: Specific Therapies For Covid-19 In People With Diabetesmentioning

confidence: 99%

Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In addition, it was reported that liraglutide could treat myocardial infarction by increasing myocardial blood flow, inhibiting cardiomyocyte apoptosis, and enhancing cardiac function [29]. It has also been found in our previous research that liraglutide can be combined with MSCs to alleviate the symptoms of ALI [30].…”

Section: Introductionmentioning

confidence: 71%

“…204656-20-2, China) (LPS + liraglutide group). The concentrations of LPS and liraglutide were selected based on previous studies of MSCs viability [30]. After 6,24,48, and 72 h of incubation, 10 μL of 5 mg/mL MTT (M2128, Sigma, USA) solution was added to each well and continued to culture at 37°C for 4 h. Cells were lysed using 100 μL of dimethylsulfoxide (DMSO, 67-68-5, Sigma, USA).…”

Section: Mtt Assaymentioning

confidence: 99%

Mesenchymal stem cells combined with liraglutide relieve acute lung injury through apoptotic signaling restrained by PKA/β-catenin

Yang

Don

et al. 2020

Stem Cell Res Ther

Self Cite

View full text Add to dashboard Cite

Background: ARDS and ALI are life-threatening diseases with extremely high mortality in patients. Different sources of MSCs could mitigate the symptoms of ALI from diverse mechanisms. Liraglutide is an activator of glucagon-like peptide-1 receptor (GLP-1R) that activates anti-apoptotic pathways and exerts anti-inflammatory effects. We mainly compared the effects of human chorionic villus-derived mesenchymal stem cells (hCMSCs), human bone marrowderived mesenchymal stem cells (hBMSCs), and human adipose-derived mesenchymal stem cells (hAMSCs) on the treatment of ALI and explored the apoptosis mechanism of combination MSCs of liraglutide. Methods: The proliferation of MSCs was detected by MTT assay. Western blot and RT-qPCR were used to detect the expression of GLP-1R, SPC, Ang-1, and KGF in MSCs stimulated by LPS and liraglutide. By using flow cytometry and TUNEL assay to compare the apoptosis of three MSCs under the action of LPS and liraglutide, we selected hCMSCs as the target cells to study the expression of apoptotic protein through the PKA/β-catenin pathway. In ALI animal models, we observed the effects of liraglutide alone, MSCs alone, and MSCs combined with liraglutide by H&E staining, cell counting, immunohistochemistry, and ELISA assay. Results: We demonstrated that LPS attenuates the proliferation of the three MSCs and the expression of GLP-1R. Liraglutide could reverse the effects of LPS; increase the expression of SPC, Ang-1, and KGF; and can reduce the apoptosis of three MSCs through the PKA/β-catenin pathway. In the LPS-induced ALI model, MSCs combined with liraglutide showed a significant therapeutic effect, and hCMSCs combined with liraglutide have advantages in the treatment of ALI. Conclusions: The therapeutic effect of combination MSCs of liraglutide on ALI was higher than that of MSCs alone or liraglutide alone, and liraglutide could alleviate the symptoms of ALI by reducing MSCs apoptosis.

show abstract

“…They are derived from the bone marrow, placental chorionic membrane and the lung respectively. Previous studies have shown that BMSCs, LRMSCs and hCMSCs play protective roles in lung injury caused by mechanical ventilation injury, endotoxin and plateau factors [6,8]. Other studies have reported that BMSCs can improve the lung injury caused by phosgene [4].…”

Section: Discussionmentioning

confidence: 99%

“…LRMSCs can signi cantly improve in ammatory response and reduce pulmonary edema in endotoxininduced lung injury [7]. HCMSCs also play a repair role in lung injury [8]. However, the speci c effects of LRMSCs and hCMSCs in phosgene inhalation lung injury have not been reported.…”

Section: Introductionmentioning

confidence: 99%

Comparison of the effects of different mesenchymal stem cells on attenuating phosgene-induced lung injury in rats

Zhou

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Phosgene-induced lung injury is an important type of acute lung injury (ALI), which mainly leads to acute pulmonary edema. Currently, no effective clinical treatment has been developed yet. In the present study, the effects of lung-resident mesenchymal stem cells (LRMSCs), bone marrow mesenchymal stem cells (BMSCs) and human chorionic villi-derived MSCs (hCMSCs) were compared in phosgene-induced lung injury of male SD rats. Methods The changes in body weight, PaO2 and respiratory indexes were recorded. Rats were sacrificed at 6 h, 24 h, and 48 h. Expressions of TNF-α, IL-1β, IL-6, HGF and IL-10 were tested by ELISA. SP-C mRNA expression was assessed by RT-PCR. The MSCs migration was assessed using Transwell migration assay and Wound-healing assay. Hepatocyte growth factor (HGF) was added to the MSCs culture medium for 48 h. Expressions of p-GSK-3β and β-catenin were determined by Western blot. Results Significant improvements in body weight, PaO2 and respiratory indexes were observed after treatment with MSCs. BMSCs produced the highest effects followed by hCMSCs and LRMSCs. Compared with the phosgene group, MSCs decreased the levels of TNF-α, IL-1β, and IL-6 and increased the levels of IL-10, HGF and SP-C. Different MSCs displayed no significant differences in proliferation. However, BMSCs showed the strongest migration ability. HGF increased the expressions of p-GSK-3β and β-catenin in MSCs. All MSCs exerted protective effects on phosgene-induced lung injury by reducing inflammation, immune regulation and restoring cell function. Conclusions BMSCs showed the best protective effects followed by hCMSCs and LRMSCs. HGF enhances the role of MSCs by activating the p-GSK-3β/β-catenin signaling pathway.

show abstract

RETRACTED ARTICLE: Effect of hCMSCs and liraglutide combination in ALI through cAMP/PKAc/β-catenin signaling pathway

Cited by 27 publications

References 36 publications

Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature

Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature

Mesenchymal stem cells combined with liraglutide relieve acute lung injury through apoptotic signaling restrained by PKA/β-catenin

Comparison of the effects of different mesenchymal stem cells on attenuating phosgene-induced lung injury in rats

Contact Info

Product

Resources

About